Barbara Klencke
Known title: DirectorCIK: 0001647647
Barbara Klencke's purchase track record
How the stock did after each of Barbara Klencke's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since December 14, 2023
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-61.7%
3 months: -24.9%
Beat the S&P 500
33%
median -68.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/23/2024 | TCRX | $26K | -42.1% | -69.2% | +0.9% |
| 8/23/2024 | TCRX | $56K | -24.9% | -61.7% | +6.7% |
| 12/14/2023 | TCRX | $25K | +35.8% | +80.0% | +15.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| XNCR | ▲ Buy | Grant | 10,302 | $0 | 6/16/2026 | View on chart |
| XNCR | ▲ Buy | Grant | 13,686 | $0 | 6/12/2025 | View on chart |
| TCRX | ▲ Buy | Open Market | 5,000 | $26K | 9/23/2024 | View on chart |
| TCRX | ▲ Buy | Open Market | 5,000 | $28K | 8/26/2024 | View on chart |
| TCRX | ▲ Buy | Open Market | 5,000 | $28K | 8/23/2024 | View on chart |
| XNCR | ▲ Buy | Grant | 5,986 | $0 | 6/13/2024 | View on chart |
| TCRX | ▲ Buy | Open Market | 5,000 | $25K | 12/14/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
XNCR: Improved Funding for Obexelimab
Xencor announced that it has secured better funding for its experimental antibody Obexelimab, which could support further development of the therapy. The news comes as the stock is near its 18‑touch support level of $12 and still below the 52‑week low of $10.38. Analysts maintain a target of $31.42, indicating that the funding may help the company move toward that goal.
XNCR: Improved Funding for Obexelimab. Xencor announced that it has secured better funding for its experimental antibody Obexelimab, which could support further development of the therapy. The news comes as the stock is near its 18‑touch support level of $12 and still below the 52‑week low of $10.38. Analysts maintain a target of $31.42, indicating that the funding may help the company move toward that goal.